Physicians' Academy for Cardiovascular Education

Familial Hypercholesterolemia

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD

Optimizing treatment for patients with HoFH

10' education - July 13, 2022 - Prof. Erik Stroes, MD, PhD

HoFH: Why is early diagnosis important?

10' education - June 29, 2022 - Prof. Kausik Ray, MD

Findings of analysis on pediatric FH patients in large global registry

3' education - June 16, 2022 - Kanika Dharmayat

Large global inequity in treatment and outcomes of HoFH

5' education - Feb. 16, 2022 - Tycho Tromp, MD

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

The mechanism of action of bempedoic acid

Feb. 2, 2020

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD
Prof. Raal presents a case of a 16-year old female with homozygous familial hypercholesterolemia (HoFH) and discusses the cumulative LDL-c lowering effects of different  therapies in this patient.

Prof. Raal presents a case of a 16-year old female with homozygous familial hypercholesterolemia (HoFH) and discusses the cumulative LDL-c lowering effects of different therapies in this patient.

Greater LDL-c reduction by PCSK9i in FH patients in time-averaged analysis

Literature - July 18, 2022 - Schludi B, et al. - J Clin Lipidol. 2022

A pooled analysis showed that calculating the average LDL-c concentration over a longer period of time demonstrated a larger LDL-c reduction by evolocumab in FH patients.

Optimizing treatment for patients with HoFH

10' education - July 13, 2022 - Prof. Erik Stroes, MD, PhD
Prof. Stroes explains that combination therapy holds the promise to achieve LDL-c target levels in patients with homozygous familial hypercholesterolemia (HoFH).

Prof. Stroes explains that combination therapy holds the promise to achieve LDL-c target levels in patients with homozygous familial hypercholesterolemia (HoFH).

HoFH: Why is early diagnosis important?

10' education - June 29, 2022 - Prof. Kausik Ray, MD
Homozygous familial hypercholesterolemia (HoFH) is a genetic condition that is associated with very high levels of LDL-c from birth. Prof. Ray shows how outcomes can be improved by earlier diagnosis and use of multiple lipid-lowering treatments.

Homozygous familial hypercholesterolemia (HoFH) is a genetic condition that is associated with very high levels of LDL-c from birth. Prof. Ray shows how outcomes can be improved by earlier diagnosis and use of multiple lipid-lowering treatments.

Findings of analysis on pediatric FH patients in large global registry

3' education - June 16, 2022 - Kanika Dharmayat
Kanika Dharmayat talks about how to achieve early identification of FH patients based on findings from an analysis of the EAS FHSC global registry on children and adolescents with FH.

EAS 2022 Kanika Dharmayat talks about how to achieve early identification of FH patients based on findings from an analysis of the EAS FHSC global registry on children and adolescents with FH.

Global registry reveals characteristics of HeFH in children and adolescents

News - May 24, 2022

EAS 2022 Data on characteristics of FH in children are critical to inform contemporary approaches to identify children/adolescents with FH worldwide.

Long-term and safe reduction of LDL-c levels with bempedoic acid

Literature - May 9, 2022 - Ballantyne CM, et al. - Am J Cardiol. 2022

In a follow-up study of the CLEAR Harmony trial, up to 2.5 years of continuous treatment with bempedoic acid was generally well tolerated and stably decreased LDL-c levels in patients with ASCVD and/or heterozygous familial hypercholesterolemia.

Large global inequity in treatment and outcomes of HoFH

5' education - Feb. 16, 2022 - Tycho Tromp, MD
There is a need for robust aggregated data on homozygous FH (HoFH). Tycho Tromp shares the first results of a study on a unique worldwide cohort of HoFH patients.

There is a need for robust aggregated data on homozygous FH (HoFH). Tycho Tromp shares the first results of a study on a unique worldwide cohort of HoFH patients.

FDA approval for PCSK9 siRNA to lower LDL-c

News - Dec. 23, 2021

The FDA has approved the small interfering RNA (siRNA) PCKS9 therapy inclisiran to lower LDL-c with two doses a year, after a first dose and one at 3 months, for treatment of adults with clinical ASCVD or FH.

Cost-effectiveness of a population genomic screening strategy for FH

Literature - Dec. 14, 2021 - Marquina C et al. - Eur Heart J. 2021

A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.

Monogenic FH and clinically defined FH remain largely undertreated

Literature - Oct. 25, 2021 - Björnsson E et al. - Arterioscler Thromb Vasc Biol. 2021

This study investigated the prevalence and impact of monogenic FH and clinically defined FH in a large proportion of the Icelandic population.

Women with FH want more information on pregnancy in relation to their condition

Literature - Oct. 20, 2021 - Klevmoen M et al. - Atherosclerosis. 2021

This study investigated the duration of pregnancy-related off-statin periods in Norwegian and Dutch women with FH. Among these women, 86% wanted to receive more information on pregnancy and breastfeeding in relation to FH.